Long COVID
231
53
77
94
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
17 trials with published results (7%)
Research Maturity
94 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.9%
2 terminated out of 231 trials
97.9%
+11.4% vs benchmark
3%
8 trials in Phase 3/4
18%
17 of 94 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 94 completed trials
Clinical Trials (231)
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
Long-Term Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Undergoing Preoperative Anesthesia Evaluation
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
NE3107 in Adults With Neurological Symptoms of Long COVID
Taurine Supplementation in Long COVID
AT1001 for the Treatment of Long COVID
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Fatigability in Long COVID-19
Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms
A Study to Examine Anktiva for the Treatment of COVID-19.
Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID
Balance Acceptance and Commitment Therapy for Long COVID
A Study to Assess Anktiva in Patients With Long Covid-19.
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)